Le Lézard
Classified in: Science and technology
Subject: PER

Systech International announces record third quarter performance



PRINCETON, N.J., Dec. 7, 2017 /PRNewswire/ -- Systech International, a global technology leader in serialization, track and trace and brand protection, today announced the company recorded its highest revenue in any third quarter and is positioned to close out its most profitable year in its 32-year history. This has been driven by the continued adoption of its comprehensive suite of software solutions. Its UniTracetm traceability software continues to expand in market share, its serialization solution is the de-facto standard for the pharma industry, and its UniSecuretm solution is gaining traction as the next evolution of true brand authentication.

Given this positive trajectory, founder Robert DeJean has announced he will retire from the day-to-day responsibilities of Chief Executive Officer to fully focus on his more strategic role as advisor and member of the board of directors. The company has enlisted an executive search firm to recruit a new CEO to continue working toward the vision to radically change the way companies build, protect, and grow their brands.

Michael Dubilier, Chairman of Systech's Board of Directors stated, "We are grateful for all Bob has done in the last 32 years to bring Systech to this critical juncture."

"With the strong leadership team in place, now is the perfect time to transition to a new CEO. I'm looking forward to working strategically with the executive team as we enter into this next exciting phase of the company," stated Mr. DeJean. "Our software platform, Uniquity, has successfully supported the serialization needs of the pharmaceutical industry for decades and we are deploying this platform to reach beyond just serialization into true brand protection and brand activation."

During our CEO search process, Kevin McKay, a longtime supporter, advisor, and consultant of Systech will be providing support to the board on certain aspects of the transition. Kevin's extensive executive experience with software solutions and services in the healthcare industry will be invaluable.

About Systech International: Systech pioneered serialization and is defining the future of authentication. For more than 30 years, Systech has led best practices for global brands across pharmaceutical, life sciences, and consumer packaged goods industries. Systech's presence includes offices in North America, Europe, India, and a partner network in South America, the Middle East, China, and Japan.

Contact:

Systech International
Sarah Paris-Mascicki
+1 7327639460
Sarah.paris@systechone.com

SOURCE Systech International


These press releases may also interest you

at 20:03
Bombardier is pleased to announce that it has reached collective bargaining agreements with the more than 2,100 production and office workers, represented by Unifor Locals 112 and 673, at its site in...

at 20:00
China is stepping into a new phase in this new age, is deeply implementing innovation-driven strategy, is speeding up building of an innovative state and is continuously promoting "Mass Entrepreneurship and Innovation" to a new level. On Jun 22,...

at 19:55
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Harbour BioMed, a global biopharmaceutical company developing...

at 17:00
Open Access publishing is gaining popularity as the world is increasingly connected online today, facilitating archiving, indexing, data mining, retrieving, and speedy distribution of researched information. Open access publishing is producing a...

at 17:00
A new global study from SMART Technologies, the world leader in education technology, gives insight into how a school's approach to planning, implementing and using technology can impact teaching and learning outcomes. Released today, the study...

at 17:00
Renovatm Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that an abstract of a study in a preclinical model of type 1 diabetes was accepted as a...




News published on 7 december 2017 at 16:37 and distributed by: